

# ACTIN Report (research use only)

PATIENT  
EXAMPLE-LUNG-01  
REPORT DATE  
17-Sep-2025

Gender: **Female** | Birth year: **1975** | WHO: **1**

Tumor: **Lung adenocarcinoma** | Lesions: **Liver, Lung** | Stage: **IV**

## Clinical summary

Relevant systemic treatment history      **6/2023-1/2025    Osimertinib**

## Recent molecular results

### Hartwig WGS (22-Feb-2025)

Biopsy location	<b>Lung (purity 50%)</b>
Molecular tissue of origin prediction	<b>Lung: Non-small cell: LUAD (98%)</b>
Tumor mutational load / burden	<b>TML 160 / TMB 14 mut/Mb</b>
Microsatellite (in)stability	<b>Stable</b>
HR status	<b>Proficient (0)</b>
Driver mutations	<b>EGFR C797S, EGFR L858R, KRAS G12C, KRAS G12D</b>
Amplified genes	<b>None</b>
Deleted genes	<b>TP53 del</b>
Homozygously disrupted genes	<b>None</b>
Gene fusions	<b>MET(exon13)::MET(exon15) fusion</b>
Driver virus	<b>None</b>

## Immunology

HLA-A	<b>HLA-A*01:01 Copy number: 1, Mutated: No</b>
	<b>HLA-A*02:01 Copy number: 0.0, Mutated: No</b>

## Trial-relevant IHC results

PD-L1	<b>Score &gt; 50%</b>
-------	-----------------------

## Phase 2/3+ trials in NL that are open and potentially eligible (2 trials)

Trial	Cohort	Molecular	Sites	Warnings
<u>METC 04</u> <u>TEDR1</u> <u>(Phase 2)</u>	Lung cancer C797S cohort	EGFR C797S	NKI-AvL	None
<u>EGFR-C797S-TRIAL</u> <u>(Phase 2)</u>	<i>EGFR C797S</i>	<i>EGFR C797S</i>	<i>Elisabeth-Tweesteden Ziekenhuis</i>	

Trials matched solely on molecular event and tumor type (no clinical data used) are shown in italicized, smaller font.

## Phase 1/2 (or unknown phase) trials in NL that are open and potentially eligible (3 trials)

Trial	Cohort	Molecular	Sites	Warnings
<u>METC 02</u> <u>KAYRAS</u> <u>(Phase 1/2)</u>	Dose expansion - monotherapy - NSCLC	KRAS G12D, PD-L1 >= 50.0	Erasmus MC	Variant(s) G12D in KRAS but subclonal likelihood of > 50%
<b>METC 01</b> <b>IEMOEN</b> <b>(Phase 1)</b>	Dose escalation - monotherapy ( <i>no slots</i> )	None		Has not exhausted SOC (at least platinum doublet remaining)

All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.

1/6 Gene and variant annotations and related content are powered by Genomenon Cancer Knowledgebase (CKB).

# ACTIN Report (research use only)

PATIENT  
**EXAMPLE-LUNG-01**  
REPORT DATE  
**17-Sep-2025**

Trial	Cohort	Molecular	Sites	Warnings
<i><a href="#">EGFR-L858R-TRIAL-(Phase 1)</a></i>	<i>EGFR L858R</i>	<i>EGFR L858R</i>	<i>Elisabeth-Tweesteden Ziekenhuis</i>	

Trials matched solely on molecular event and tumor type (no clinical data used) are shown in italicized, smaller font.

## International trials that are open and potentially eligible (1 trial)

Trial	Cohort	Molecular	Sites
<i><a href="#">KRAS-G12C-TRIAL-DE-(Phase 1)</a></i>	<i>KRAS G12C</i>	<i>KRAS G12C</i>	<i>Germany: Stuttgart</i>

Trials in this table are matched solely on molecular event and tumor type (clinical data excluded).

1 trial filtered due to trials recruiting nationally for the same molecular target. See Other Trial Matching Results for filtered matches.

# ACTIN Report (research use only)

PATIENT  
EXAMPLE-LUNG-01  
  
REPORT DATE  
17-Sep-2025

## Molecular Details

### Hartwig WGS (EXAMPLE-LUNG-01-T, 22-Feb-2025)

#### General

Purity	Ploidy	TML Status	TMB Status	MS Stability	HR Status	DPYD	UGT1A1
50%	2.3	High (160)	High (14)	Stable	Proficient (0)	*1_HOM (Normal function)	*1_HOM (Normal function)

#### Predicted tumor origin

##### 1. Lung: Non-small cell: LUAD

Combined prediction score	98%
---------------------------	-----

This score is calculated by combining information on:

(1) SNV types	60%
(2) SNV genomic localisation distribution	70%
(3) Driver genes and passenger characteristics	80%

Other cohorts have a combined prediction of 2% or lower

#### Key drivers

Type	Driver	Trials (Locations)	Trials in Hartwig	Best evidence in External	Resistance in External
Mutation (gain of function)	EGFR L858R (2/4 copies)		NCT00000006	Approved	
Mutation (gain of function)	EGFR C797S (1/4 copies)	TEDR1 (NKI-AvL)	NCT00000008	Pre-clinical	
Mutation (gain of function)	KRAS G12D (0.3/2 copies)*	KAYRAS (Erasmus MC)			
Mutation (gain of function)	KRAS G12C (0.3/2 copies)*		NCT00000009		
Deletion	TP53 del				

The table continues on the next page

# ACTIN Report (research use only)

PATIENT  
EXAMPLE-LUNG-01  
  
REPORT DATE  
17-Sep-2025

Continued from the previous page

Type	Driver	Trials (Locations)	Trials in Hartwig	Best evidence in External	Resistance in External
Known fusion	MET(exon13)::MET(exon15) fusion domain(s) kept: Tyrosine Kinase domain(s) lost: Juxtamembrane				

\* Variant has > 50% likelihood of being sub-clonal

## Other drivers or relevant events

None

## Immunology

HLA gene	Type	Tumor copy number	Mutated in tumor
HLA-A	HLA-A*01:01	1	No
	HLA-A*02:01	0.0	No

## IHC results

PD-L1

**Score > 50%**

All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.

# ACTIN Report (research use only)

PATIENT  
EXAMPLE-LUNG-01  
REPORT DATE  
17-Sep-2025

## Clinical Details

### Clinical summary

Relevant systemic treatment history	6/2023-1/2025	Osimertinib
Relevant other oncological history		<b>None</b>
Previous primary tumor		<b>None</b>
Relevant non-oncological history	2023	Rheumatoid arthritis

### Patient current details (20-Feb-2025)

Unresolved toxicities grade => 2	<b>None</b>
LVEF	50%
Known allergies	<b>None</b>
Recent surgeries	01-Aug-2024 Cholecystectomy

### Tumor details (20-Feb-2025)

Measurable disease	<b>Yes</b>
Known lesions	<b>Liver, Lung</b>
No lesions present	<b>CNS, Brain, Bone, Lymph node</b>

### Active medication details

Medication	Administration route	Start date	Stop date	Dosage	Frequency
St. John's Wort	Oral	01-Feb-2023		300 MILLIGRAMS	1 / 2 DAYS

### Blood transfusions

Product	Date
ERTHROCYTES_FILTERED	20-Sep-2024

## Trial Matching Details

### Filtered trials potentially eligible based on molecular results which are potentially recruiting (1 trial)

Trial	Cohort	Molecular	Sites
<a href="#">EGFR-BE (Phase 1)</a>	<i>EGFR L858R</i>	<i>EGFR L858R</i>	<i>Belgium: Brussels</i>

### Trials and cohorts that are potentially eligible, but are closed (1 trial)

Trial	Cohort	Molecular	Sites	Warnings
<a href="#">METC 01 IEMOEN (Phase 1)</a>	Dose expansion - monotherapy	None		Has not exhausted SOC (at least platinum doublet remaining)

### Trials and cohorts that are considered ineligible (4 cohorts from 3 trials)

Trial	Cohort	Molecular	Ineligibility reasons
<a href="#">METC 02 KAYRAS (Phase 1/2)</a>	Dose expansion - monotherapy - Colorectum	KRAS G12D, PD-L1 >= 50.0	No colorectal cancer
<a href="#">METC 03 NO-SEE797ES</a>	Dose escalation - monotherapy	EGFR C797S	C797S in EGFR in canonical transcript
<a href="#">METC 05 PICKME3CA</a>	<i>Applies to all cohorts below</i>  Dose expansion - monotherapy - NSCLC <i>(closed)</i> Dose expansion - monotherapy - Other cancer types <i>(closed)</i>	None	No PIK3CA activating mutation(s)  Tumor belongs to DOID term(s) lung non-small cell carcinoma

### Trials and cohorts that are not evaluable or ignored (0 trials)

None